CA2941401C — Treatment of intrahepatic cholestatic diseases
Assigned to CymaBay Therapeutics Inc · Expires 2019-06-11 · 7y expired
What this patent protects
Intrahepatic cholestatic diseases, such as primary biliary cirrhosis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, and Alagille syndrome, may be treated by the administration of (R)-2-(4-((2-ethoxy-3-(4- (trifluoromethyl)phenoxy)propyl)thio)-2-me…
USPTO Abstract
Intrahepatic cholestatic diseases, such as primary biliary cirrhosis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, and Alagille syndrome, may be treated by the administration of (R)-2-(4-((2-ethoxy-3-(4- (trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy) acetic acid [MBX-8025] and its salts.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.